European Journal of Clinical Pharmacology

, Volume 14, Issue 6, pp 375–381 | Cite as

Acute and chronic effects of nifedipine in arterial hypertension

  • O. Lederballe Pedersen
  • E. Mikkelsen


Sublingual administration of nifedipine 10 mg to 11 patients and 20 mg to 6 patients with arterial hypertension caused a rapid and significant decrease in blood pressure in both groups. The average maximal reductions in the two groups were 21/16 mm Hg and 27/21 mm Hg. A concomitant rise in heart rate was found. Forearm blood flow showed a significant increase and the calculated vascular resistance a significant decrease 15–60 min after administration of both the 10 mg and the 20 mg doses. There was a negative correlation between basal vascular resistance and the maximal change of this parameter (r=−0.72, p<0.01). Plasma concentrations of nifedipine showed considerable individual variation, with slow absorption in some patients, which indicated failure of sublingual absorption in them. The difference between the mean plasma concentration in the two dose groups was statistically significant after 45 min. A negative correlation was present between the plasma concentration of nifedipine and the observed change in calculated vascular resistance (r=−0.74 at t=30 min). Treatment of 10 hypertensive patients with nifedipine 30–60 mg daily for 6 weeks reduced mean blood pressure from 175/115 mm Hg to 151/96 mm Hg (p<0.001). Heart rate and forearm blood flow rose, whereas the forearm vascular resistance showed a significant decrease. Side effects of a sensation of heat and reddening of face were noted in some patients. It is suggested that nifedipine may be useful both in the acute and chronic treatment of arterial hypertension.

Key words

Arterial hypertension antihypertensive therapy calcium antagonists nifedipine forearm hemodynamics 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aoki, K., Yoshida, T., Kato, S., Tazumi, K., Sato, I., Takikawa, K., Hotta, K.: Hypotensive action and increased plasma renin activity by Ca2+ antagonist (Nifedipine) in hypertensive patients. Jap. Heart J.17, 479–484 (1976)Google Scholar
  2. Atterhög, J.-H., Ekelund, L.-G., Melin, A.-L.: Effect of nifedipine on exercise tolerance in patients with angina pectoris. Europ. J. clin. Pharmacol.8, 125–130 (1975)Google Scholar
  3. Chrysant, S. G., Dunn, F. G., de Carvalho, J. G. R., Adamopoulos, P. N., Frohlich, E. D.: Action of nitroglycerin and amyl nitrite in labile and essential hypertension. Arch. int. Med.137, 1702–1705 (1977)Google Scholar
  4. Collier, J. G., Lorge, R. E., Robinson, B. F.: Comparison of effects of tolmesoxide (RX71107), diazoxide, hydrallazine, prazosin, glyceryl trinitrate and sodium nitroprussid on forearm arteries and dorsal hand veins of man. Br. J. clin. Pharmacol.5, 35–44 (1978)Google Scholar
  5. Fleckenstein, A., Tritthart, H., Döring, H. J., Byon, K. Y.: BAY a 1040 — ein hochaktiver Ca++-antagonistischer Inhibitor der elektromechanischen Koppelungsprozesse im Warmblütermyokard. Arzneim.-Forsch.22, 22–23 (1972)Google Scholar
  6. Gribbin, B., Pickering, T. G., Sleight, P., Peto, R.: Effect of age and high blood pressure on baroreflex sensitivity in man. Circ. Res.29, 424–431 (1971)Google Scholar
  7. Grün, G., Fleckenstein, A.: Die elektromechanische Entkoppelung der glatten Gefäßmuskulatur als Grundprinzip der Coronardilatation durch 4-(2′-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäure-dimethylester (BAY a 1040, Nifedipine). Arzneim.-Forsch.22, 334–344 (1972)Google Scholar
  8. Guazzi, M., Olivari, M. T., Polese, A., Fiorentini, C., Magrini, F., Moruzzi, P.: Nifedipine, a new antihypertensive with rapid action. Clin. Pharmacol. Therap.22, 528–532 (1977)Google Scholar
  9. Jacobsen, P., Lederballe Pedersen, O., Mikkelsen, E.: Gas chromatographic determination of nifedipine and one of its metabolites using electron capture detection. J. Chromatogr. (In press) (1978)Google Scholar
  10. Klütsch, K., Schmidt, P., Grosswendt, J.: Der Einfluß von BAY a 1040 auf die Nierenfunktion des Hypertonikers. Arzneim.-Forsch.22, 377–380 (1972)Google Scholar
  11. Koch-Weser, J.: Vasodilator drugs in the treatment of hypertension. Arch. int. Med.133, 1017–1027 (1974)Google Scholar
  12. Laaser, U., Meurer, K. A., Kaufmann, W.: Zur klinischen Bewertung der Kombinationsbehandlung von Nifedipin mit verschiedenen Antihypertensiva. Arzneim.-Forsch.27, 676–681 (1977)Google Scholar
  13. Lederballe Pedersen, O.: Does verapamil have a clinically significant antihypertensive effect? Europ. J. clin. Pharmacol.13, 21–24 (1978).Google Scholar
  14. Lederballe Pedersen, O., Mikkelsen, E., Andersson, K.-E.: Effects of extracellular calcium on potassium and noradrenaline induced contractions in the aorta of spontaneously hypertensive rats — Increased sensitivity to nifedipine. Acta pharmacol. toxicol.43, 137–144 (1978)Google Scholar
  15. Mikkelsen, E., Andersson, K.-E., Lederballe Pedersen, O.: The effect of nifedipine on isolated human peripheral vessels. Acta pharmacol. toxicol. (In press) (1978a)Google Scholar
  16. Mikkelsen, E., Andersson, K.-E., Lederballe Pedersen, O.: Verapamil and nifedipine inhibition of contractions induced by potassium and noradrenaline in human mesenterial arteries and veins. Acta Pharmacol. toxicol. (In press) (1978b)Google Scholar
  17. Mostbeck, A., Partsch, H., Peschl, L.: Investigations on peripheral blood distribution. 3rd International Adalat® Symposium, p. 91–97. Amsterdam: Excerpta Medica 1976Google Scholar
  18. Murakami, M., Murakami, E., Takekoshi, N., Tsuchiya, M., Kin, T., Onoe, T., Takeuchi, N., Funatsu, T., Hara, S., Ishise, S., Mifune, J., Maeda, M.: Antihypertensive effect of 4(-2′-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarbonic acid dimethylester (Nifedipine, BAY a 1040), a new coronary dilator. Jap. Heart J.13, 128–135 (1972)Google Scholar
  19. Raschack, M.: Differences in the cardiac actions of the calcium antagonists verapamil and nifedipine. Arzneim.-Forsch.26, 1330–1333 (1976)Google Scholar
  20. Rämsch, K. D.: Nifedipine: Fluoreszenzspektroskopische Nachweismethode der unveränderten Substanz im Blutplasma nach Gabe therapeutischer Dosen. (To be published)Google Scholar
  21. Tarazi, R. C., Dustan, H. P., Bravo, E. L., Niarchos, A. P.: Vasodilating drugs: contrasting haemodynamic effects. Clin. Sci. mol. Med.51, 575s-578s (1976)Google Scholar

Copyright information

© Springer-Verlag 1978

Authors and Affiliations

  • O. Lederballe Pedersen
    • 1
  • E. Mikkelsen
    • 1
  1. 1.Department of clinical Pharmacology and Department of Medicine I, Aarhus AmtssygehusUniversity of AarhusDenmark

Personalised recommendations